SRRK - Scholar Rock Holding Corporation Price-to-Projected Revenue Ratio

Scholar Rock (SRRK) - corporate logo

Scholar Rock enjoys high credibility for its innovations in muscle atrophy therapy. The forward price-to-sales valuation reflects the current market value, where the metric stands at 9272.00. Business prospects depend on competing with industry behemoths in the field of gene therapy, while financial stability relies exclusively on the success of clinical trials and the inflow of investments.

Scholar Rock, Inc. - SRRK Projected Price to Revenue (period 07/04/2022 - 11/15/2026)

Analytical breakdowns for Scholar Rock

- market price and analyst price targets:
Price Chart Scholar Rock Corp|SRRK - Price Target Chart
- market capitalization statistics:
Market Value Scholar Rock Inc.|SRRK - Total Enterprise Value
- book value of equity indicators:
Book Value per Share Scholar Rock|SRRK - Book Value of Business|Market Cap to Net Assets Ratio scholarrock.com|SRRK - Company Assets
- debt and liquidity data:
Debt to Equity Scholar Rock|SRRK - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Capital Scholar Rock, Inc.|SRRK - Company Total Debt|Debts to Book Capitalization Scholar Rock, Inc.|SRRK - Company Long-Term Loans and Borrowings|Company Short-Term Debt Scholar Rock|Quick Liquidity scholarrock.com
- financial results and valuation multiples details:
SRRK - Company Net Income|Projected Future Earnings Scholar Rock|SRRK - P/E Multiple|Future Price to Earnings Scholar Rock|SRRK - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Scholar Rock, Inc.|SRRK - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Scholar Rock|SRRK - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months scholarrock.com|SRRK - Earnings per share growth rate in current year|Earnings growth forecast for next year Scholar Rock
- revenue and sales proceeds data:
SRRK - Company Sales|Company Projected Revenue Scholar Rock, Inc.|SRRK - P/S Multiple|Price-to-Projected Revenue Ratio Scholar Rock Corp|SRRK - Annual Revenue Growth (Last Twelve Months)
Analysis of all company metrics:Scholar Rock Corp SRRK
Original product of Scholar Rock Inc.

For the biotech sector, where Scholar Rock (SRRK) depends on clinical trial outcomes, the expected P/S multiple allows for a comparison of current market value against projected revenue from future drugs. This calculation eliminates time lags between reports, helping investors determine the extent of overpayment for potential earnings and assess the asset's resilience amid regulatory risks.

Key competitors

Price-to-Projected Revenue Ratio Jazz Pharma JAZZ|Cytokinetics Corp - Price-to-Projected Revenue Ratio|PTCT - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Centessa Pharmaceuticals|DYN (Dyne Corp) - Forward Price-to-Revenue Multiple|Projected Price to Revenue Edgewise Pharma EWTX|Forward Price-to-Revenue Multiple RAPP|Market Cap to Future Revenue Ratio Alumis Corp ALMS|Forward Price-to-Revenue Multiple ZVRA (Kempharm)|Forward Price-to-Revenue Multiple contineum-tx.com CTNM|Forward P/S Multiple LRMR (larimartx.com)|Forward P/S Multiple Capricor Therapeutics CAPR|TRDA: Forward Price-to-Revenue Multiple|PTHS - Forward P/S Multiple|MNOV: Forward P/S Multiple|Market Cap to Projected Revenue SER|BTAI (BioXcel Therapeutics Inc) - Forward P/S Multiple|ProMIS Neurosciences, Inc. (PMN) - Market Cap to Expected Sales Ratio|Forward P/S Multiple APUS|Price-to-Projected Revenue Ratio AEON (AEON Biopharma, Inc.)|Forward P/S Multiple NLSP (NLS Pharmaceutics Ltd.)|Market Cap to Expected Sales Ratio Bionomics Ltd (BNOX)|HUGE - Price-to-Projected Revenue Ratio|Forward Price to Sales RETA (Reata Pharmaceuticals, Inc.)